article Open AccessTop 1% cited

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

JNCI Journal of the National Cancer Institute · 2008 · Vol. 100(9) · pp. 672–679

X. Li✉(Baylor College of Medicine)Michael T. Lewis(Baylor College of Medicine)Jian Huang(Baylor College of Medicine)Carolina Gutiérrez(Baylor College of Medicine)C. Kent Osborne(Baylor College of Medicine)M.-F. Wu(Baylor College of Medicine)S. G. Hilsenbeck(Baylor College of Medicine)Anne C. Pavlick(Baylor College of Medicine)Xiaolei Zhang(Baylor College of Medicine)Gary C. Chamness(Baylor College of Medicine)Hiu Yung Wong(Baylor College of Medicine)Jeffrey M. Rosen(Baylor College of Medicine)Jenny C. Chang(Baylor College of Medicine)

View via DOI Publisher page

Abstract

These studies provide clinical evidence for a subpopulation of chemotherapy-resistant breast cancer-initiating cells. Lapatinib did not lead to an increase in these tumorigenic cells, and, in combination with conventional therapy, specific pathway inhibitors may provide a therapeutic strategy for eliminating these cells to decrease recurrence and improve long-term survival.

Cancer Cells and Metastasis HER2/EGFR in Cancer Research Breast Cancer Treatment StudiesLapatinibBreast cancerCD44MedicineInternal medicineChemotherapyOncologyCancerPopulationCD24

MeSH terms

LapatinibAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleFlow CytometryHumansMiddle AgedNeoplasm Recurrence, LocalQuinazolinesReceptors, EstrogenReceptors, ProgesteroneResearch Design

Citations

1,789

FWCI

55.75

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health